Akuta et al. also recently demonstrated that all eight NAFLD patients with SGLT2 administration relieved hepatic steatosis and three of them obtained improvement in liver fibrosis [47]. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.